Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Accretion Nutraveda IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2021 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 17.75 Cr
Profile
Price Range 122  to  129 per share
Profile
Min Investment ₹129
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Our Company is in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. We are a healthcare focused Company specialising in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. We offer a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Since its inception in 2021, our Company has established itself as a reliable Contract Development and Manufacturing Organization (CDMO), offering specialized services to a wide range of clients across various industries. Our product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support. We also manufacture Capsules, including hard gelatin and HPMC capsules, targeting areas like liver detoxification, women’s health, and cognitive support. Our oral liquids include syrups, suspensions, and tonics, which are particularly suited for paediatric and geriatric segments. Additionally, we produce Traditional Ayurvedic Powders known as churans for digestive health, medicated ayurvedic oils for musculoskeletal and dermatological applications using traditional processes, and a range of external preparations like balms, ointments, creams, and gels for pain relief, skin care, and hair care. Read More

Basic Info

Face Value 10 per share

Price 122  to  129 per share

P/E (x) 1.8

Sales( Cr.) 16

PAT( Cr.) 3

EPS 71.9

Draft Prospectus

Exchange BSE-SME

Promoter

Company Promoters

Mayur Popatlal Sojitra Ankurkumar Shantilal Patel Paraskumar Vinubhai Parmar Hardik Mukundbhai Prajapati Harshad Nanubhai Rathod Vivek Ashok Kumar Patel

Pre Issue Share Holding 100%

Post Issue Share Holding 67.96%

Listing Details:

Listing Price: 191

Listing Gain: 32.46%

Current Price: 261.5

Gain On Issue: 261.5 | 0%

GMP: 68

GMP %: 52.7 %

IPO Tentative Timetable

Opening Date Jan 28, 2026
Closing Date Jan 30, 2026
Allotment Feb 02, 2026
Refund Feb 03, 2026
Delivery of Shares Feb 03, 2026
Listing Date Feb 04, 2026

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 2000 258,000
Retail (Max) -- -- --
S-HNI (Min) 1 2000 258,000
S-HNI (Max) 3 6000 774,000
B-HNI (Min) 4 8000 1,032,000

Objective of the Issue

1) Purchase of Machineries for Automation in existing Manufacturing unit 2) Purchase of Machineries for New Manufacturing Setup 3) Funding working capital requirements of our company 4) General corporate purposes

Issue

Category Nos Bid Bid (x)
QIB 364000 367000 1x
NII 372000 669000 1.8x
Retail 640000 1404000 2.2x
EMP 0 0 0x
Total 1376000 2440000 1.8x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Accretion Nutraveda Profit & Loss

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 3 5 16
Other Income 0 0 0
Total Income 3 5 16
Total Expenditure 2 4 12
Operating Profit 1 1 4
Interest 0 0 0
Depreciation 0 0 0
Exceptional Income / Expenses 0 0 0
Profit Before Tax 0 1 3
Provision for Tax 0 0 1
Profit After Tax 0 1 3
Adjustments 0 0 0
Profit After Adjustments 0 1 3
Adjusted Earnings Per Share 0.8 2.3 5.4

Accretion Nutraveda Balance Sheet

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 0 1 5
Minority's Interest 0 0 0
Borrowings 1 1 2
Other Non-Current Liabilities 0 0 0
Total Current Liabilities 2 3 4
Total Liabilities 4 5 11
Fixed Assets 1 1 2
Other Non-Current Assets 0 0 0
Total Current Assets 3 3 9
Total Assets 4 5 11

Accretion Nutraveda Cash Flow

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0
Cash Flow from Operating Activities 1 0 -2
Cash Flow from Investing Activities -0 -0 -1
Cash Flow from Financing Activities -1 -0 3
Net Cash Inflow / Outflow 0 0 -0
Closing Cash & Cash Equivalent 0 0 0

Accretion Nutraveda Ratios

# Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.78 2.28 5.37
CEPS(Rs) 1.64 3.01 5.86
DPS(Rs) 0 0 0
Book NAV/Share(Rs) 0.73 3.01 10.98
Core EBITDA Margin(%) 21.41 24.45 23.26
EBIT Margin(%) 16.48 23.06 22.09
Pre Tax Margin(%) 9.9 18.27 19.88
PAT Margin (%) 9.67 16.42 16.33
Cash Profit Margin (%) 20.39 21.65 17.84
ROA(%) 6.91 18.9 33.71
ROE(%) 106.65 121.94 81.22
ROCE(%) 21.4 42 56.72
Receivable days 100.61 38.28 40.1
Inventory Days 162.84 133.99 79.49
Payable days 354.92 161.86 30.77
PER(x) 0 0 0
Price/Book(x) 0 0 0
Dividend Yield(%) 0 0 0
EV/Net Sales(x) 0.77 0.48 0.27
EV/Core EBITDA(x) 2.85 1.71 1.15
Net Sales Growth(%) 0 72.41 219.7
EBIT Growth(%) 0 141.17 206.37
PAT Growth(%) 0 192.91 217.9
EPS Growth(%) 0 192.93 134.99
Debt/Equity(x) 7.5 2 0.72
Current Ratio(x) 1.07 1.07 2.24
Quick Ratio(x) 0.53 0.29 1.08
Interest Cover(x) 2.5 4.82 9.96
Total Debt/Mcap(x) 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 220% 0% 0% 0%
Operating Profit CAGR 300% 0% 0% 0%
PAT CAGR 200% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 81% 103% 103% 103%
ROCE Average 57% 40% 40% 40%

Company Contact Information

Accretion Nutraveda Ltd.

Payal Hareshbhai Kotadiya

91- 9904366177

compliance@accretionnutraveda.com

Plot No. 27 Xcelon Industrial Park–1, Vasna Chacharawadi Ta-sanand, Behind Intas Pharmaceutical, Changodar

IPO Lead Manager(s)

Accretion Nutraveda Ltd.

Sobhagya Capital Options Ltd

Registrar Info

Accretion Nutraveda Ltd.

KFIN Technologies Ltd.

301, The Centrium, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai, Mumbai, Maharashtra, India, 400070

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!